Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
3.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
4.

Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.

Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V.

Acta Clin Belg. 2010 Sep-Oct;65(5):300-4.

PMID:
21128555
5.

Cardiac effects of adjuvant therapy for early breast cancer.

Theodoulou M, Seidman AD.

Semin Oncol. 2003 Dec;30(6):730-9. Review.

PMID:
14663774
6.

Adjuvant therapy for breast cancer.

Hennessy BT, Pusztai L.

Minerva Ginecol. 2005 Jun;57(3):305-26. Review.

PMID:
16166938
7.

[Adjuvant chemotherapy of early stage breast cancer].

Boér K.

Orv Hetil. 2010 Feb 28;151(9):344-53. doi: 10.1556/OH.2010.28824. Review. Hungarian.

PMID:
20159750
8.

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

Bird BR, Swain SM.

Clin Cancer Res. 2008 Jan 1;14(1):14-24. doi: 10.1158/1078-0432.CCR-07-1033. Review.

9.

Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2007 Dec;8 Suppl 1:S11-21. Review.

PMID:
18282366
10.

Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.

Du F, Yuan P, Zhu W, Wang J, Ma F, Fan Y, Xu B.

Med Oncol. 2014 Dec;31(12):340. doi: 10.1007/s12032-014-0340-x. Epub 2014 Nov 22.

PMID:
25416049
11.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
12.

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

Perez EA.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20. Review.

PMID:
18777950
13.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

14.
15.

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.

Ewer MS, O'Shaughnessy JA.

Clin Breast Cancer. 2007 Jun;7(8):600-7. Review.

PMID:
17592672
16.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
17.

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.

Crozier JA, Swaika A, Moreno-Aspitia A.

World J Clin Oncol. 2014 Aug 10;5(3):529-38. doi: 10.5306/wjco.v5.i3.529. Review.

18.

Controversies in the therapy of early stage breast cancer.

Cianfrocca M, Gradishar WJ.

Oncologist. 2005 Nov-Dec;10(10):766-79. Review.

19.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24. Review.

PMID:
15107948
20.

Use of non-anthracycline regimens in early stage breast cancer in Australia.

de Boer RH, Chan A, Tran B, Wilcken N.

Asia Pac J Clin Oncol. 2011 Mar;7(1):4-10. doi: 10.1111/j.1743-7563.2010.01353.x. Epub 2010 Dec 22. Review.

PMID:
21332644

Supplemental Content

Support Center